Grifols: to invest 35 million dollars in US biotech firm.
(CercleFinance.com) - Spain's Grifols has agreed to buy a 44 percent stake in San Francisco-based biotech company GigaGen, for 35 million dollars, in a move to strengthen its R&D portfolio.
Grifols's innovation unit GIANT has also entered into a research and collaboration agreement with GigaGen, in exchange for a collaboration fee of 15 million dollars.
Under the terms of the agreement, GigaGen will carry out research activities to develop recombinant polyclonal immunoglobulin therapies derived from human B cells for the treatment of human diseases.
GigaGen's technology captures immune repertoires and uses them as novel biotherapeutics.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Grifols's innovation unit GIANT has also entered into a research and collaboration agreement with GigaGen, in exchange for a collaboration fee of 15 million dollars.
Under the terms of the agreement, GigaGen will carry out research activities to develop recombinant polyclonal immunoglobulin therapies derived from human B cells for the treatment of human diseases.
GigaGen's technology captures immune repertoires and uses them as novel biotherapeutics.
Copyright (c) 2017 CercleFinance.com. All rights reserved.